Crinetics Pharmaceuticals (CRNX)
(Real Time Quote from BATS)
$53.85 USD
+0.51 (0.96%)
Updated Jul 26, 2024 12:28 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Crinetics Pharmaceuticals, Inc. [CRNX]
Reports for Purchase
Showing records 61 - 80 ( 87 total )
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Demonstrates Innovative Capabilities With ACTH-Inhibitor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Steady Progress With Acrobat Readouts Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Which Endocrine Companies to See and Why at Our 32nd Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas Weekly Recap of Our Key Notes and 9 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Expectations Going Into Ph1 PK/PD Data for CRN01941 in 1Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $37/share price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $37/share price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Another Quarter of Quiet Execution, POC for Key Programs Upcoming in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Update Serves as a Reminder That Crinetics Is More than Acromegaly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D